Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Ungaro

Showing results (141-150 of 386) with videos related to

Pageof 39
Sort By:
Alimentary Pharmacology & Therapeutics|January 22, 2019
Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factorsManasi Agrawal, Shirley Cohen-Mekelburg, Maia Kayal, et al.
Artificial Intelligence in Medicine|November 26, 2024
Electronic Health Records-based identification of newly diagnosed Crohn's Disease casesSusanne Ibing, Julian Hugo, Florian Borchert, et al.
Inflammatory Bowel Diseases|September 26, 2025
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic AcidAndres Yarur, Peter Irving, Britta Siegmund, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2023
Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER)Jean-Frederic Colombel, Ryan C Ungaro, Bruce E Sands, et al.
Journal of Crohn'S & Colitis|May 16, 2019
Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel DiseaseRyan C Ungaro, Andres Yarur, Jacqueline Jossen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2021
COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United StatesManasi Agrawal, Erica J Brenner, Joyce Wing Yan Mak, et al.
Gut|October 21, 2020
Effect of IBD medications on COVID-19 outcomes: results from an international registryRyan C Ungaro, Erica J Brenner, Richard B Gearry, et al.
Neuromuscular Disorders : NMD|August 21, 2007
A novel Angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern ItalyF L Conforti, T Sprovieri, R Mazzei, et al.
Therapeutic Advances in Gastroenterology|November 9, 2022
COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case-control studySimon J Hong, Sumona Bhattacharya, Aiya Aboubakr, et al.
Inflammatory Bowel Diseases|August 31, 2023
Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA ConsensusShubha Bhat, Ruishen Lyu, Mitali Agarwal, et al.
Pageof 39

Showing results (141-150 of 386) with videos related to

Sort By:
Pageof 39
Alimentary Pharmacology & Therapeutics|January 22, 2019
Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factorsManasi Agrawal, Shirley Cohen-Mekelburg, Maia Kayal, et al.
Artificial Intelligence in Medicine|November 26, 2024
Electronic Health Records-based identification of newly diagnosed Crohn's Disease casesSusanne Ibing, Julian Hugo, Florian Borchert, et al.
Inflammatory Bowel Diseases|September 26, 2025
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic AcidAndres Yarur, Peter Irving, Britta Siegmund, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2023
Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER)Jean-Frederic Colombel, Ryan C Ungaro, Bruce E Sands, et al.
Journal of Crohn'S & Colitis|May 16, 2019
Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel DiseaseRyan C Ungaro, Andres Yarur, Jacqueline Jossen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2021
COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United StatesManasi Agrawal, Erica J Brenner, Joyce Wing Yan Mak, et al.
Gut|October 21, 2020
Effect of IBD medications on COVID-19 outcomes: results from an international registryRyan C Ungaro, Erica J Brenner, Richard B Gearry, et al.
Neuromuscular Disorders : NMD|August 21, 2007
A novel Angiogenin gene mutation in a sporadic patient with amyotrophic lateral sclerosis from southern ItalyF L Conforti, T Sprovieri, R Mazzei, et al.
Therapeutic Advances in Gastroenterology|November 9, 2022
COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case-control studySimon J Hong, Sumona Bhattacharya, Aiya Aboubakr, et al.
Inflammatory Bowel Diseases|August 31, 2023
Defining the Roles of Inflammatory Bowel Disease Clinical Pharmacists in the United States: A Systematic Review and National RAND/UCLA ConsensusShubha Bhat, Ruishen Lyu, Mitali Agarwal, et al.
Pageof 39